Physician profile
Brian Contreras
NPI 1023571783
$2,970.91
in general payments reported to CMS, 2019-2025
27 companies · $16.60 in 2025
The $16.60 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $527 · 2021: $229 · 2022: $348 · 2023: $580 · 2024: $563 · 2025: $16.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $721.63 | 2020-2025 | Farxiga, Airsupra, Fasenra |
| Janssen Pharmaceuticals, INC | $391.59 | 2019-2022 | |
| Novo Nordisk INC | $359.17 | 2019-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $275.15 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.78 | 2020-2024 | Jardiance |
| Lilly USA, LLC | $120.31 | 2020-2024 | Zepbound, Mounjaro |
| Abbvie INC. | $115.03 | 2023 | Avycaz |
| Melinta Therapeutics, LLC | $104.79 | 2020-2022 | |
| Exact Sciences Corporation | $93.86 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $93.67 | 2019 | |
| Paratek Pharmaceuticals, INC. | $89.33 | 2019 | |
| Pfizer INC. | $60.59 | 2021-2024 | |
| La Jolla Pharmaceutical Company | $51.66 | 2021 | |
| Mylan Specialty L.P. | $50.08 | 2020 | |
| Glaxosmithkline, LLC. | $49.67 | 2022-2024 | Trelegy Ellipta, Shingrix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $47.23 | 2019 | |
| Shield Therapeutics INC | $37.13 | 2023 | Accrufer |
| Novartis Pharmaceuticals Corporation | $27.50 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $22.95 | 2022 | |
| Celgene Corporation | $19.64 | 2023 | Zeposia |
| Medtronic, INC. | $19.56 | 2021 | |
| Tris Pharma INC | $18.90 | 2023 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $18.43 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $16.70 | 2020 | |
| Nevro Corp. | $16.08 | 2023 | Senza |
| Chiesi USA, INC. | $15.47 | 2022 | |
| Amgen INC. | $14.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Contreras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.